Rohit R. Bhosale1*, Dhanashri D. Chavan2, Vandana M. Thorat2
1Department of Pharmaceutics, Krishna Foundation’s Jaywant Institute of Pharmacy, Wathar, Tal. Karad- 415539, Dist. Satara, Maharashtra, India https://orcid.org/0000-0002-6423-1524
2Department of Pharmacology, Krishna Vishwa Vidyapeeth (KVV) Deemed to be University, Karad- 415539, Dist. Satara, Maharashtra, India
*Address for Corresponding Author
Dr. Rohit R. Bhosale
Department of Pharmaceutics,
Krishna Foundation’s Jaywant Institute of Pharmacy, Wathar, Tal. Karad-415539, Dist. Satara, Maharashtra, India
Abstract
Cell-based immunotherapy is currently one of the most exciting developments in the fight against cancer, and to date, cellular therapies have been approved for people with certain blood cancers, but the cell therapy for solid tumors has yet to achieve that same milestone. Solid tumors comprise about 90% of all cancer diagnoses, thereby indicating more research on cell therapy technology as well as scalable production that could expand this treatment to the larger number of people with cancer. Cell therapy uses the living cells as a drug to treat disease, and when used to treat cancer, cell therapy takes advantage of the immune system’s intrinsic ability to seek out and destroy abnormal cells in the body. Developing cell therapies to attack cancer cells for solid tumors, to persist in the body and overcome tumor’s ability to hide from the immune system, has been notoriously difficult. With the technologies available, cell therapy is very expensive and difficult to produce in scalable quantities.
Keywords: Cell-based therapy, virtues, cancer management, regulatory aspects
